A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.

Authors

Sylvia Mina Lee

University of Washington - Seattle Cancer Care Alliance, Seattle, WA

Sylvia Mina Lee , Missak Haigentz Jr., Liza Cosca Villaruz , Igor Gorbatchevsky , Sam Suzuki , Susie Tanamly , Nancy Louise Samberg , Maria Fardis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.

First Author: Amir A. Jazaeri

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.

First Author: Amod Sarnaik

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.

First Author: Daniel Olson

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.

First Author: Jason Alan Chesney